Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure.

Fransen S, Karmochkine M, Huang W, Weiss L, Petropoulos CJ, Charpentier C.

Antimicrob Agents Chemother. 2009 Oct;53(10):4522-4. doi: 10.1128/AAC.00651-09. Epub 2009 Aug 10.

We characterized the raltegravir (RAL) susceptibility and the integrase (IN)-mediated replication capacity (RC) of RAL-resistant human immunodeficiency virus type 1 from two patients experiencing virologic failure during continuous RAL salvage therapy. The following two distinct outcomes were observed: (i) the selective outgrowth of virus with high-level RAL resistance and high IN-mediated RC leading to significant viral load rebound and (ii) the selection of virus with a slight reduction in RAL susceptibility and low IN-mediated RC resulting in sustained low-level viremia.

PMID: 19667293

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.